Quest Diagnostics Current Ratio 2012-2026 | DGX
Current and historical current ratio for Quest Diagnostics (DGX) from 2012 to 2026. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Quest Diagnostics current ratio for the three months ending March 31, 2026 was 0.00.
| Quest Diagnostics Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2026-03-31 | $2.57B | $2.18B | 1.18 |
| 2025-12-31 | $2.38B | $2.28B | 1.04 |
| 2025-09-30 | $2.41B | $2.13B | 1.13 |
| 2025-06-30 | $2.20B | $2.02B | 1.09 |
| 2025-03-31 | $2.08B | $1.44B | 1.44 |
| 2024-12-31 | $2.39B | $2.17B | 1.10 |
| 2024-09-30 | $2.62B | $2.09B | 1.25 |
| 2024-06-30 | $2.02B | $2.01B | 1.00 |
| 2024-03-31 | $2.23B | $2.30B | 0.97 |
| 2023-12-31 | $2.37B | $1.82B | 1.31 |
| 2023-09-30 | $1.82B | $1.62B | 1.12 |
| 2023-06-30 | $1.73B | $1.88B | 0.92 |
| 2023-03-31 | $1.81B | $1.36B | 1.34 |
| 2022-12-31 | $1.90B | $1.55B | 1.22 |
| 2022-09-30 | $2.33B | $1.60B | 1.46 |
| 2022-06-30 | $2.43B | $1.58B | 1.54 |
| 2022-03-31 | $2.48B | $1.70B | 1.46 |
| 2021-12-31 | $2.74B | $1.75B | 1.56 |
| 2021-09-30 | $2.85B | $1.76B | 1.62 |
| 2021-06-30 | $2.15B | $1.55B | 1.38 |
| 2021-03-31 | $3.00B | $1.71B | 1.76 |
| 2020-12-31 | $3.06B | $1.78B | 1.72 |
| 2020-09-30 | $3.35B | $2.39B | 1.40 |
| 2020-06-30 | $2.38B | $1.84B | 1.29 |
| 2020-03-31 | $1.56B | $1.13B | 1.38 |
| 2019-12-31 | $2.49B | $1.99B | 1.25 |
| 2019-09-30 | $1.78B | $2.01B | 0.89 |
| 2019-06-30 | $1.57B | $1.90B | 0.82 |
| 2019-03-31 | $1.78B | $2.28B | 0.78 |
| 2018-12-31 | $1.39B | $1.49B | 0.94 |
| 2018-09-30 | $1.60B | $1.39B | 1.15 |
| 2018-06-30 | $1.42B | $1.26B | 1.12 |
| 2018-03-31 | $1.37B | $1.12B | 1.23 |
| 2017-12-31 | $1.31B | $1.06B | 1.24 |
| 2017-09-30 | $1.54B | $1.05B | 1.47 |
| 2017-06-30 | $1.50B | $0.92B | 1.64 |
| 2017-03-31 | $1.56B | $0.99B | 1.58 |
| 2016-12-31 | $1.53B | $0.98B | 1.56 |
| 2016-09-30 | $1.64B | $1.05B | 1.57 |
| 2016-06-30 | $1.51B | $1.11B | 1.36 |
| 2016-03-31 | $1.49B | $1.09B | 1.37 |
| 2015-12-31 | $1.50B | $1.17B | 1.28 |
| 2015-09-30 | $1.65B | $1.13B | 1.46 |
| 2015-06-30 | $1.53B | $1.24B | 1.23 |
| 2015-03-31 | $2.38B | $2.09B | 1.14 |
| 2014-12-31 | $1.60B | $1.71B | 0.94 |
| 2014-09-30 | $1.56B | $1.19B | 1.31 |
| 2014-06-30 | $1.51B | $1.26B | 1.20 |
| 2014-03-31 | $1.49B | $1.19B | 1.25 |
| 2013-12-31 | $1.38B | $1.13B | 1.22 |
| 2013-09-30 | $1.43B | $1.24B | 1.15 |
| 2013-06-30 | $1.47B | $1.29B | 1.14 |
| 2013-03-31 | $1.46B | $1.21B | 1.21 |
| 2012-12-31 | $1.56B | $1.05B | 1.49 |
| 2012-09-30 | $1.47B | $1.07B | 1.38 |
| 2012-06-30 | $1.48B | $1.33B | 1.12 |
| 2012-03-31 | $1.52B | $1.53B | 1.00 |
| 2011-12-31 | $1.40B | $1.56B | 0.90 |
| 2011-09-30 | $1.40B | $1.76B | 0.79 |
| 2011-06-30 | $1.48B | $1.99B | 0.74 |
| 2011-03-31 | $2.30B | $1.77B | 1.30 |
| 2010-12-31 | $1.61B | $1.21B | 1.32 |
| 2010-09-30 | $1.55B | $1.15B | 1.35 |
| 2010-06-30 | $1.63B | $1.00B | 1.64 |
| 2010-03-31 | $1.65B | $1.08B | 1.53 |
| 2009-12-31 | $1.68B | $1.06B | 1.59 |
| 2009-09-30 | $1.47B | $0.99B | 1.48 |
| 2009-06-30 | $1.34B | $1.02B | 1.31 |
| 2009-03-31 | $1.49B | $1.27B | 1.17 |
| 2008-12-31 | $1.50B | $1.23B | 1.22 |
| 2008-09-30 | $1.55B | $1.24B | 1.25 |
| 2008-06-30 | $1.42B | $1.13B | 1.25 |
| 2008-03-31 | $1.47B | $1.19B | 1.23 |
| 2007-12-31 | $1.37B | $1.29B | 1.07 |
| 2007-09-30 | $1.45B | $1.20B | 1.21 |
| 2007-06-30 | $1.42B | $1.16B | 1.22 |
| 2007-03-31 | $1.25B | $1.57B | 0.80 |
| 2006-12-31 | $1.19B | $1.15B | 1.04 |
| 2006-09-30 | $1.24B | $1.18B | 1.06 |
| 2006-06-30 | $1.22B | $1.11B | 1.10 |
| 2006-03-31 | $1.20B | $1.13B | 1.06 |
| 2005-12-31 | $1.07B | $1.10B | 0.97 |
| 2005-09-30 | $1.15B | $1.19B | 0.97 |
| 2005-06-30 | $1.15B | $0.94B | 1.22 |
| 2005-03-31 | $1.04B | $0.93B | 1.12 |
| 2004-12-31 | $0.93B | $1.04B | 0.89 |
| 2004-09-30 | $1.11B | $0.78B | 1.43 |
| 2004-06-30 | $1.04B | $0.77B | 1.36 |
| 2004-03-31 | $1.07B | $0.66B | 1.62 |
| 2003-12-31 | $1.00B | $0.72B | 1.38 |
| 2003-09-30 | $0.97B | $0.67B | 1.44 |
| 2003-06-30 | $0.95B | $0.67B | 1.43 |
| 2003-03-31 | $0.91B | $0.67B | 1.35 |
| 2002-12-31 | $0.82B | $0.64B | 1.30 |
| 2002-09-30 | $0.93B | $0.86B | 1.08 |
| 2002-06-30 | $0.93B | $0.95B | 0.99 |
| 2002-03-31 | $0.95B | $0.62B | 1.52 |
| 2001-12-31 | $0.88B | $0.66B | 1.33 |
| 2001-09-30 | $0.99B | $0.89B | 1.11 |
| 2001-06-30 | $0.96B | $0.89B | 1.08 |
| 2001-03-31 | $0.95B | $0.92B | 1.04 |
| 2000-12-31 | $0.98B | $0.96B | 1.03 |
| 2000-09-30 | $1.05B | $0.99B | 1.06 |
| 2000-06-30 | $0.96B | $0.72B | 1.34 |
| 2000-03-31 | $0.83B | $0.62B | 1.33 |
| 1999-12-31 | $0.87B | $0.70B | 1.24 |
| 1999-09-30 | $0.88B | $0.64B | 1.37 |
| 1999-06-30 | $0.53B | $0.31B | 1.68 |
| 1999-03-31 | $0.53B | $0.31B | 1.72 |
| 1998-12-31 | $0.58B | $0.31B | 1.87 |
| 1998-09-30 | $0.56B | $0.30B | 1.85 |
| 1998-06-30 | $0.55B | $0.28B | 1.98 |
| 1998-03-31 | $0.58B | $0.30B | 1.94 |
| 1997-12-31 | $0.57B | $0.30B | 1.94 |
| 1997-09-30 | $0.55B | $0.28B | 1.98 |
| 1997-06-30 | $0.52B | $0.25B | 2.08 |
| 1997-03-31 | $0.52B | $0.24B | 2.15 |
| 1996-12-31 | $0.51B | $0.25B | 2.05 |
| 1996-09-30 | $0.00B | 0.00 | |
| 1996-06-30 | $0.00B | 0.00 | |
| 1996-03-31 | $0.00B | 0.00 | |
| 1995-12-31 | $0.50B | $0.30B | 1.67 |
| 1995-09-30 | $0.00B | 0.00 | |
| 1995-06-30 | $0.00B | 0.00 | |
| 1995-03-31 | $0.00B | 0.00 | |
| 1994-12-31 | $0.00B | 0.00 | |
| 1994-09-30 | $0.00B | 0.00 | |
| 1994-06-30 | $0.00B | 0.00 | |
| 1994-03-31 | $0.00B | 0.00 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Outpatient & Home Care | $21.197B | $11.035B |
| Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fresenius SE (FSNUY) | Germany | $29.514B | 13.37 |
| Elanco Animal Health (ELAN) | United States | $11.500B | 24.35 |
| Encompass Health (EHC) | United States | $10.662B | 19.64 |
| DaVita (DVA) | United States | $10.023B | 13.82 |
| Chemed (CHE) | United States | $5.639B | 19.57 |
| Option Care Health (OPCH) | United States | $4.553B | 18.71 |
| RadNet (RDNT) | United States | $4.302B | 142.13 |
| LifeStance Health (LFST) | United States | $2.495B | 320.00 |
| Addus HomeCare (ADUS) | United States | $1.719B | 16.61 |
| Astrana Health (ASTH) | United States | $1.536B | 31.40 |
| Aveanna Healthcare Holdings (AVAH) | United States | $1.353B | 12.20 |
| U.S Physical Therapy (USPH) | United States | $1.157B | 29.19 |
| Pennant (PNTG) | United States | $1.072B | 31.31 |
| Daxor (DXR) | United States | $0.048B | 0.00 |
| MEDIROM Healthcare Technologies (MRM) | Japan | $0.032B | 0.00 |
| Psychemedics (PMD) | United States | $0.000B | 0.00 |